Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

NCT02942758 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Due to financial reasons.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: low-dose Azacitidine
DRUG: Pioglitazone
DRUG: ATRA
DRUG: standard-dose AZA

Sponsor

University Hospital Regensburg

Collaborators

[object Object]
[object Object]